🇺🇸 FDA
Patent

US 12215162

BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 12215162 (BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof) held by The Board of Regents of the University of Texas System expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/48